EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT05020704
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Registry
-
NCT05020704
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Unknown status
Technical summary
Registry record NCT05020704. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-16 (actual); primary completion 2024-06-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
- Acronym
- EMPRESS-MI
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Collaborator
- University of Glasgow
Record details
- Record id
cardio:ct-nct05020704- Content hash
78f5da9323a45bb5d8952dc7596337d3b7cf4e51d7e83efa8aba99a8241d783a